INVERSAGO-PHARMA
7.9.2021 14:02:05 CEST | Business Wire | Press release
Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL) from Health Canada on July 29, 2021, it has dosed the first volunteers with INV-202 in its first-in-human phase 1 clinical trial, which will evaluate the safety, tolerability and pharmacokinetics of this compound.
As a next generation peripheral CB1 inverse agonist / antagonist, INV-202 has the potential to treat various metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D), diabetic nephropathy and chronic kidney diseases, among others.
“Having demonstrated pharmacological characteristics that exceeded our expectations during IND-enabling preclinical studies, we’re excited to launch a second peripherally-acting CB1 blocker into the clinic with INV-202,” said Dr. Glenn Crater, MD, Chief Medical Officer of Inversago Pharma.
“With two unique, next generation CB1 blockers having entered the clinic in less than a year, we are rapidly bolstering our knowledge of this new class of drugs, which we believe may provide new treatment options for patients affected by a range of metabolic conditions,” said François Ravenelle, PhD, Chief Executive Officer of Inversago.
About INV-202
INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions. It is specifically designed to preferentially interact with peripheral CB1 receptors located in the gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers. The peripheral CB1 blockade is a well-documented pathway, linked to many clinically meaningful metabolic benefits.
About Inversago Pharma
Headquartered in Montreal, Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as PWS, NASH, T1D and diabetic nephropathy. For more information, visit inversago.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005183/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Organigram Global Accelerates Integration of Sanity Group Under Unified Global Operating Structure20.8.2026 12:00:00 CEST | Press release
Leadership, operations and market development aligned across a global platform connecting Canada with Germany and other priority international markets Sanity Group integration marks the next phase of Organigram’s global growth strategy Finn Age Hänsel appointed President, Rest of World & Chief Strategy Officer Adrian Frenzel appointed Global Chief Operating Officer Tim Emberg to continue as President, Canada Organigram’s integrated supply and commercial network will span Canada, Germany, Switzerland, Poland, Czechia, the United Kingdom and Australia Sanity contributed approximately CAD$40 million to consolidated net revenue in Organigram’s most recent quarter, representing over 35% of net revenue, and was accretive to Adjusted EBITDA Sanity has demonstrated a strong growth trajectory, with quarterly revenue increasing 34% since December 31, 2025 to €25.5 million Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram” or the “Company”) today announced an important milestone in its
NTT DATA and Palo Alto Networks Sign Global Strategic Alliance to Accelerate Secure AI Transformation20.8.2026 12:00:00 CEST | Press release
First-of-its-kind global alliance combines AI-powered security innovation with enterprise-scale consulting and managed services Helps organizations navigate Frontier AI with integrated governance, threat intelligence and cybersecurity expertise Backed by co-innovation, shared engineering, coordinated global delivery and more than 2,000 Palo Alto Networks-certified professionals NTT DATA, a global leader in AI, digital business and technology services, and Palo Alto Networks (NASDAQ: PANW) today announced a multi-year strategic alliance designed to help organizations securely adopt AI, modernize cybersecurity, simplify complex technology environments and build cyber resilience for the AI era. As Palo Alto Networks first strategic alliance of this kind with a global systems integrator, the agreement, which targets $1 billion in joint business by the end of three years (2029), combines Palo Alto Networks AI-powered cybersecurity platforms with NTT DATA's consulting, engineering and manage
Packaging Redesigns See 4% Average Volume Lift, NIQ Finds20.8.2026 12:00:00 CEST | Press release
Liquid I.V., Hostess, Back to Nature, and five other brands named 2026 NIQ Design Impact Award winners NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today named the winners of its ninth annual Design Impact Awards, recognizing eight package redesigns that combined stronger shopper experiences with measurable commercial performance. Across nearly a decade of NIQ Design Impact Award winners, recognized redesigns have been associated with an average volume increase of approximately 4%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819712595/en/ NIQ Design Impact Awards 2026 The 2026 NIQ Design Impact Award Winners*:Aval French Cider (Parent Company: Aval Cider; Country: USA) Liquid I.V. (Parent Company: Unilever; Country: USA) Root & Splendor (Parent Company: Root & Splendor; Country: USA) Hostess Cakes (Parent Company: The J.M. Smucker Company; Country: USA) Back to Nature (Parent Company: Barilla Group;
BOCHK and Ant International Forge Strategic Partnership to Enhance Cross-border Payment Connectivity and Innovative Corporate Financial Service Solutions Through Fintech20.8.2026 09:00:00 CEST | Press release
Ant International and Bank of China (Hong Kong) (“BOCHK”) announced that the two parties have forged a strategic partnership. Leveraging BOCHK’s banking strengths and Ant International’s leading fintech and AI technologies, the two parties seek to explore the frontier of AI-driven innovative financial services, empower real-time treasury management and cross-border payments, deliver efficient and intelligent liquidity management and financial service solutions for global enterprises, while continuously enhancing financial services for small and medium-sized enterprises (“SMEs”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260820387312/en/ From left to right: Kelvin Li, General Manager of Platform Tech and Senior Vice President of Ant International, Eric Jing, Chairman of Ant International, Sun Yu, Vice Chairman and Chief Executive of BOCHK, and Wang Huabin, Deputy Chief Executive of BOCHK Sun Yu, Vice Chairman and Chief E
BOCHK and Ant International Forge Strategic Partnership to Enhance Cross-border Payment Connectivity and Innovative Corporate Financial Service Solutions Through Fintech20.8.2026 08:00:00 CEST | Press release
Ant International and Bank of China (Hong Kong) (“BOCHK”) announced that the two parties have forged a strategic partnership. Leveraging BOCHK’s banking strengths and Ant International’s leading fintech and AI technologies, the two parties seek to explore the frontier of AI-driven innovative financial services, empower real-time treasury management and cross-border payments, deliver efficient and intelligent liquidity management and financial service solutions for global enterprises, while continuously enhancing financial services for small and medium-sized enterprises (“SMEs”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819555366/en/ From left to right: Kelvin Li, General Manager of Platform Tech and Senior Vice President of Ant International, Eric Jing, Chairman of Ant International, Sun Yu, Vice Chairman and Chief Executive of BOCHK, and Wang Huabin, Deputy Chief Executive of BOCHK Sun Yu, Vice Chairman and Chief E
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom